Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals's Climate Target Data Preview
As of 2024, Hikma Pharmaceuticals has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 absolute reduction target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Hikma Pharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  a | 2030 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Verified Sources Behind Hikma Pharmaceuticals’s Climate Targets Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hikma Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Insights into Hikma Pharmaceuticals's Greenhouse Gas Emissions Pathways
As of 2024, Hikma Pharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions. a
Does Hikma Pharmaceuticals have a target to reduce the emissions from its operations?
As of 2024, Hikma Pharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources. a
Hikma Pharmaceuticals's most ambitious operational target is to reduce these emissions by 25% by 2030, compared to a baseline of 144,899 Metric Tonnes of CO2 equivalent (mtCO2e) in 2020. a
As of 2024, Hikma Pharmaceuticals is ahead of schedule on its operational emissions reduction target, having achieved 68% of the planned reduction. a